PMID- 37559880
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230811
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Print)
IS  - 2049-9450 (Linking)
VI  - 19
IP  - 2
DP  - 2023 Aug
TI  - Kallikrein-related peptidase 13 expression and clinicopathological features in 
      lung squamous cell carcinoma.
PG  - 64
LID - 10.3892/mco.2023.2660 [doi]
LID - 64
AB  - Lung squamous cell carcinoma (LSCC) is associated with poor prognosis. Molecular 
      targeting drugs have been demonstrated to be effective for lung adenocarcinoma; 
      however, they are often not effective for LSCC. Kallikrein-related peptidase 13 
      (KLK13) expression enhances the malignancy of lung adenocarcinoma; however, its 
      expression and crucial role in LSCC remain largely unknown. The present study 
      examined the relationship between the KLK13 expression and clinicopathological 
      features of LSCC. A total of 94 patients diagnosed with LSCC who underwent 
      lobectomy, segmentectomy or wedge resection were selected. KLK13 expression was 
      evaluated through immunostaining of formalin-fixed paraffin-embedded sections of 
      surgical specimens. Of the 94 LSCC samples, 70 exhibited no KLK13 expression, 
      while the remaining 24 exhibited ectopic expression. KLK13 expression in tumors 
      was focal and restricted to the cytoplasm of keratinized cells. LSCC cases were 
      classified into KLK13-negative and KLK13-positive groups, and KLK13 expression 
      was positively associated with E-cadherin expression (P=0.0143). Associations 
      between KLK13 expression and keratinization (P=0.0052) or absence of lymphatic 
      vessel invasion (P=0.0603) were observed; however, these trends did not reach 
      statistical significance. The present findings indicated that KLK13 expression in 
      keratinized LSCC may have a protective role in lymphatic vessel invasion of LSCC, 
      which suggests its significance for therapeutic applications against LSCC.
CI  - Copyright: (c) Sumiya et al.
FAU - Sumiya, Ryusuke
AU  - Sumiya R
AD  - Communal Laboratory, Research Institute, National Center for Global Health and 
      Medicine, Tokyo 162-8655, Japan.
AD  - Department of Thoracic Surgery, National Center for Global Health and Medicine, 
      Tokyo 162-8655, Japan.
FAU - Yamada, Kazuhiko
AU  - Yamada K
AD  - Department of Surgery, National Center for Global Health and Medicine, Tokyo 
      162-8655, Japan.
FAU - Hagiwara, Teruki
AU  - Hagiwara T
AD  - Communal Laboratory, Research Institute, National Center for Global Health and 
      Medicine, Tokyo 162-8655, Japan.
FAU - Nagasaka, Satoshi
AU  - Nagasaka S
AD  - Department of Thoracic Surgery, National Center for Global Health and Medicine, 
      Tokyo 162-8655, Japan.
FAU - Miyazaki, Hideki
AU  - Miyazaki H
AD  - Pathology Division of Clinical Laboratory, National Center for Global Health and 
      Medicine, Tokyo 162-8655, Japan.
FAU - Igari, Toru
AU  - Igari T
AD  - Pathology Division of Clinical Laboratory, National Center for Global Health and 
      Medicine, Tokyo 162-8655, Japan.
FAU - Kawamura, Yuki I
AU  - Kawamura YI
AD  - Communal Laboratory, Research Institute, National Center for Global Health and 
      Medicine, Tokyo 162-8655, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230706
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC10407464
OTO - NOTNLM
OT  - kallikrein-related peptidase 13
OT  - lung squamous cell carcinoma
OT  - lymphatic vessel invasion
COIS- The authors declare that they have no competing interests.
EDAT- 2023/08/10 06:43
MHDA- 2023/08/10 06:44
PMCR- 2023/07/06
CRDT- 2023/08/10 04:06
PHST- 2022/12/02 00:00 [received]
PHST- 2023/05/15 00:00 [accepted]
PHST- 2023/08/10 06:44 [medline]
PHST- 2023/08/10 06:43 [pubmed]
PHST- 2023/08/10 04:06 [entrez]
PHST- 2023/07/06 00:00 [pmc-release]
AID - MCO-19-2-02660 [pii]
AID - 10.3892/mco.2023.2660 [doi]
PST - epublish
SO  - Mol Clin Oncol. 2023 Jul 6;19(2):64. doi: 10.3892/mco.2023.2660. eCollection 2023 
      Aug.